JP2009268467A5 - - Google Patents

Download PDF

Info

Publication number
JP2009268467A5
JP2009268467A5 JP2009147075A JP2009147075A JP2009268467A5 JP 2009268467 A5 JP2009268467 A5 JP 2009268467A5 JP 2009147075 A JP2009147075 A JP 2009147075A JP 2009147075 A JP2009147075 A JP 2009147075A JP 2009268467 A5 JP2009268467 A5 JP 2009268467A5
Authority
JP
Japan
Prior art keywords
polypeptide
acid sequence
amino acid
helper cells
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009147075A
Other languages
English (en)
Japanese (ja)
Other versions
JP4969610B2 (ja
JP2009268467A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009268467A publication Critical patent/JP2009268467A/ja
Publication of JP2009268467A5 publication Critical patent/JP2009268467A5/ja
Application granted granted Critical
Publication of JP4969610B2 publication Critical patent/JP4969610B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2009147075A 1999-09-09 2009-06-19 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用 Expired - Lifetime JP4969610B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39309099A 1999-09-09 1999-09-09
US09/393,090 1999-09-09
US16461699P 1999-11-10 1999-11-10
US60/164,616 1999-11-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006231402A Division JP2007045830A (ja) 1999-09-09 2006-08-28 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010098317A Division JP2010233571A (ja) 1999-09-09 2010-04-21 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Publications (3)

Publication Number Publication Date
JP2009268467A JP2009268467A (ja) 2009-11-19
JP2009268467A5 true JP2009268467A5 (2) 2010-07-01
JP4969610B2 JP4969610B2 (ja) 2012-07-04

Family

ID=26860707

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2001522273A Expired - Lifetime JP4505166B2 (ja) 1999-09-09 2000-09-08 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2006231402A Withdrawn JP2007045830A (ja) 1999-09-09 2006-08-28 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2009147075A Expired - Lifetime JP4969610B2 (ja) 1999-09-09 2009-06-19 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2010098317A Withdrawn JP2010233571A (ja) 1999-09-09 2010-04-21 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2013040389A Pending JP2013128489A (ja) 1999-09-09 2013-03-01 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2014206652A Expired - Fee Related JP6140122B2 (ja) 1999-09-09 2014-10-07 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2001522273A Expired - Lifetime JP4505166B2 (ja) 1999-09-09 2000-09-08 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2006231402A Withdrawn JP2007045830A (ja) 1999-09-09 2006-08-28 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010098317A Withdrawn JP2010233571A (ja) 1999-09-09 2010-04-21 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2013040389A Pending JP2013128489A (ja) 1999-09-09 2013-03-01 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2014206652A Expired - Fee Related JP6140122B2 (ja) 1999-09-09 2014-10-07 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用

Country Status (15)

Country Link
EP (1) EP1210434B2 (2)
JP (6) JP4505166B2 (2)
KR (1) KR100894359B1 (2)
CN (1) CN100529076C (2)
AR (1) AR035560A1 (2)
AT (1) ATE389019T1 (2)
AU (2) AU780163B2 (2)
CA (1) CA2388562C (2)
DE (1) DE60038304T3 (2)
ES (1) ES2300276T5 (2)
HK (1) HK1044170B (2)
HU (1) HU230679B1 (2)
IL (1) IL148300A0 (2)
MX (1) MXPA02002684A (2)
WO (1) WO2001018051A2 (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202362B2 (en) * 1999-09-03 2011-06-23 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
CA2408571C (en) 2000-05-10 2014-04-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US7510709B2 (en) 2002-10-30 2009-03-31 Genentech, Inc. Method of treating inflammatory disease by inhibition of IL-17 production
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途;関連試薬
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
EP1623011B1 (en) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
EP1522858A1 (en) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2292758A3 (en) * 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) * 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JPWO2009133863A1 (ja) * 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ep1アゴニストを含有してなる免疫増強剤
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
IN2015KN00329A (2) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014171721A1 (ko) * 2013-04-16 2014-10-23 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
KR101625112B1 (ko) 2013-04-16 2016-05-27 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
WO2015042705A1 (en) 2013-09-24 2015-04-02 Medicenna Biopharma Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
JP6219875B2 (ja) * 2015-04-10 2017-10-25 株式会社スクウェア・エニックス ネットワークゲームシステム、ゲーム装置及びプログラム
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2019073299A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
CN114317430A (zh) * 2021-12-28 2022-04-12 河北银丰鼎诚生物技术有限公司 一种适用于脐血来源免疫细胞扩增的培养液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE366311T1 (de) * 1989-12-22 2007-07-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
PE20000183A1 (es) * 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2661199A (en) * 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods

Similar Documents

Publication Publication Date Title
JP2009268467A5 (2)
JP2008536483A5 (2)
JP2012532601A5 (2)
JP2005120106A5 (2)
JP2010065037A5 (2)
JP2018138049A5 (2)
JP2010529860A5 (2)
JP2012126742A5 (2)
JP2011528896A5 (2)
JP2009225798A5 (2)
JP2010534684A5 (2)
JP2013048638A5 (2)
JP2006149406A5 (2)
RU2016106583A (ru) Пептиды, способные реактивировать мутанты р53
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
JP2010227108A5 (2)
JP2010512160A5 (2)
JP2010532656A5 (2)
JP2011511933A5 (2)
PH12012502272A1 (en) Biological materials related to her3
JP2015525217A5 (2)
JP2008538183A5 (2)
JP2011530309A5 (2)
JP2011528895A5 (2)
JP2012115277A5 (2)